{"id":"W4220862006","doi":"10.3324/haematol.2021.279459","title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"National Cancer Institute; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Celgene; Pharmacyclics; Sanofi; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Neutropenia; Gastroenterology; Population; Adverse effect; Multiple myeloma; Lenalidomide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002036954,0.0001985645,0.001023605,0.0003206285,0.0002419722,0.000007070084,0.0002786073,0.00006394868,0.0004377549],"category_scores_gemma":[0.0003313803,0.0001188673,0.000142253,0.001638158,0.0001557151,0.00003700383,0.0002339764,0.0003998594,0.000001637048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002227121,"about_ca_system_score_gemma":0.0002188244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001319436,"about_ca_topic_score_gemma":0.003737249,"domain_scores_codex":[0.997495,0.0003220971,0.000561426,0.0003864508,0.0008926979,0.0003423423],"domain_scores_gemma":[0.9982929,0.0003573624,0.0003592953,0.0007072426,0.000173221,0.0001100374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1179413,0.02128137,0.8516452,0.0000576022,0.001955086,0.002554738,0.001829525,0.0001305477,0.0001067718,0.00000371028,0.00003237857,0.002461748],"study_design_scores_gemma":[0.06654081,0.03156823,0.8972174,0.00002750899,0.001014192,0.00004301181,0.002141457,0.001140237,0.0001409694,0.000001287327,0.00003708933,0.000127825],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974696,0.00002626383,0.000003595708,0.00002039419,0.00007376283,0.002048441,0.0001422961,0.00001827852,0.0001973929],"genre_scores_gemma":[0.9995047,0.000004544112,0.0001032564,0.00001149658,0.000004188029,0.0001740533,0.0001080284,0.00001412792,0.00007554291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05140055,"threshold_uncertainty_score":0.4847266,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03769452657367144,"score_gpt":0.3114860319042406,"score_spread":0.2737915053305691,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}